Kinoshita Junko, Kitamura Kaoru, Tanaka Shinji, Sugimachi Keishi, Ishida Mayumi, Saeki Hiroshi
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Surgery. 2002 Jan;131(1 Suppl):S222-5. doi: 10.1067/msy.2002.119792.
Recently, PEA3 has been reported to suppress HER-2/neu overexpression by promoter activity and thereby inhibit tumorigenesis of breast cancer both in vitro and in vivo.
The expression of PEA3 and the clinicopathologic features of 89 patients with breast cancer were investigated. The expression of PEA3 was immunohistochemically detected in 42 (47.2%) of 89 patients.
The correlation between the expression of PEA3 and the clinicopathologic features were nil with regard to lymph node metastasis, hormone receptor, blood vessel invasion, and lymphatic vessel invasion. The disease-free survival rate was shorter for the PEA3-negative groups than for the PEA3-positive ones, but with no statistically significant difference. The overall survival rate after surgical resection in patients who were PEA3-positive vs PEA3-negative was 100% vs 87.2%, respectively, at 3 years and 89.8% vs 72.7%, respectively, at 6 years (P =.0472).
The expression of PEA3 in breast cancer might therefore be a novel prognostic factor.
最近，有报道称PEA3可通过启动子活性抑制HER-2/neu的过表达，从而在体外和体内抑制乳腺癌的肿瘤发生。
研究了89例乳腺癌患者的PEA3表达及临床病理特征。89例患者中，42例（47.2%）通过免疫组织化学检测到PEA3表达。
PEA3表达与淋巴结转移、激素受体、血管侵犯和淋巴管侵犯等临床病理特征之间无相关性。PEA3阴性组的无病生存率低于PEA3阳性组，但差异无统计学意义。PEA3阳性与PEA3阴性患者手术切除后的总生存率在3年时分别为100%和87.2%，在6年时分别为89.8%和72.7%（P = 0.0472）。
因此，PEA3在乳腺癌中的表达可能是一个新的预后因素。
